Real-world study reveals how well new liver cancer combo works in patients with cirrhosis
NCT ID NCT07193316
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how safe and effective a combination of two drugs (Atezolizumab and Bevacizumab) is for people with liver cancer and cirrhosis, compared to standard pills (tyrosine kinase inhibitors). Researchers followed 38 patients to see how long they lived and how their liver function changed. The goal was to fill in gaps from earlier clinical trials by studying patients with mild liver problems in everyday medical practice.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CIRRHOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fondazione Policlinico Agostino Gemelli IRCCS
Roma, 00168, Italy